Business
from24/7 Wall St.
2 days agoPhathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target
Barclays upgraded Phathom Pharmaceuticals to Overweight, raising the price target to $18, citing an attractive entry point ahead of expected revenue growth.